We are live on ! Find out more
ACM

AH Capital Management Portfolio holdings

AUM $14.2B
1-Year Est. Return 20.01%
This Fund
S&P 500
This Quarter Est. Return
+10.39%
1 Year Est. Return
-20.01%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$14.2B
AUM Growth
+$12.9B
Cap. Flow
+$12.5B
Cap. Flow %
87.87%
Top 10 Hldgs %
99.38%
Holding
19
New
3
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
SPCX
SpaceX
SPCX
+$12.7B
2
RBLX icon
Roblox
RBLX
+$13.7M
3
KLRA
Kailera Therapeutics
KLRA
+$3.08M

Top Sells

Rank Stock Value
1
FIG
Figma
FIG
+$202M
2
NAUT icon
Nautilus Biotechnolgy
NAUT
+$22.7M
3
OMDA
Omada Health Inc
OMDA
+$18.4M

Sector Composition

Rank Sector Weight
1 Industrials 89.97%
2 Technology 5.85%
3 Healthcare 3.21%
4 Communication Services 0.95%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPCX
1
SpaceX
SPCX
$2.01T
$12.8B 89.97%
+74,855,020
New +$12.7B
NAVN
2
Navan Inc
NAVN
$5.56B
$645M 4.54%
28,218,676
– –
RVMD icon
3
Revolution Medicines
RVMD
$40.9B
$173M 1.21%
921,099
– –
META icon
4
Meta Platforms (Facebook)
META
$1.7T
$120M 0.84%
212,531
– –
FIG
5
Figma
FIG
$12.1B
$108M 0.76%
5,983,308
-10,028,070
-63% -$202M
BIOA
6
BioAge Labs
BIOA
$370M
$79.2M 0.56%
3,233,170
– –
XYZ
7
Block Inc
XYZ
$45.8B
$77.3M 0.54%
1,016,697
– –
ERAS icon
8
Erasca
ERAS
$5.17B
$52.4M 0.37%
2,862,500
– –
MAZE
9
Maze Therapeutics
MAZE
$1.25B
$50.8M 0.36%
1,702,225
– –
DMRA
10
Damora Therapeutics
DMRA
$1.39B
$32.2M 0.23%
1,236,157
– –
OMDA
11
Omada Health Inc
OMDA
$1.25B
$25.3M 0.18%
1,153,639
-1,153,645
-50% -$18.4M
NAUT icon
12
Nautilus Biotechnolgy
NAUT
$123M
$16.9M 0.12%
9,063,054
-8,590,863
-49% -$22.7M
RBLX icon
13
Roblox
RBLX
$34.2B
$14.9M 0.11%
+274,570
New +$13.7M
AKTS
14
Aktis Oncology
AKTS
$1.22B
$13.4M 0.09%
415,000
– –
CAMP icon
15
CAMP4 Therapeutics
CAMP
$266M
$9.29M 0.07%
2,125,339
– –
BTGO
16
BitGo Holdings
BTGO
$889M
$3.45M 0.02%
666,356
– –
KLRA
17
Kailera Therapeutics
KLRA
$1.66B
$3.08M 0.02%
+140,000
New +$3.08M
DNA icon
18
Ginkgo Bioworks
DNA
$531M
$1.08M 0.01%
108,568
– –
IPST
19
IP Strategy Holdings
IPST
$1.99M
$9.72K ﹤0.01%
4,137
– –

Similar funds

CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
AAMU
APG Asset Management US New York $14.3B AUM 16.79% 1-Year Est. Return
NYLIM
New York Life Investment Management New York $14.3B AUM 34.42% 1-Year Est. Return
AM
Atreides Management Boston, Massachusetts $14.3B AUM 116.01% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $14.1B AUM 39.89% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
ZIG
Zurich Insurance Group Zurich, Switzerland $14.4B AUM 63.77% 1-Year Est. Return

AH Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, AH Capital Management held 19 positions worth $14.2B, up 1,001% from $1.29B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

AH Capital Management deployed $12.5B of net new capital in Q2 2026, opening 3 new positions. Its largest new stake was SpaceX: 74,855,020 shares worth $12.8B.

By sector, the portfolio is most concentrated in Industrials at 90% of assets, followed by Technology and Healthcare.

On the sell side, the largest reduction was Figma, an estimated $202M trimmed.

  • AH Capital Management's largest Q2 2026 buy was SpaceX: 74,855,020 shares worth $12.8B.
  • AH Capital Management's biggest Q2 2026 reduction was Figma, cutting an estimated $202M.
  • AH Capital Management's ten largest holdings make up 99% of its $14.2B portfolio in Q2 2026.
  • AH Capital Management opened 3 new positions and closed 0 in Q2 2026.
  • AH Capital Management's portfolio value rose 1,001% quarter-over-quarter to $14.2B.

Based on AH Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.